Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 406 citing articles:

Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease
Alan Chait, Laura J. den Hartigh
Frontiers in Cardiovascular Medicine (2020) Vol. 7
Open Access | Times Cited: 1031
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 574
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Mengwei Li, Xiaowei Chi, Ying Wang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 405
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi, et al.
Kidney International (2018) Vol. 94, Iss. 1, pp. 26-39
Open Access | Times Cited: 324
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Takao Sato, Yoshifusa Aizawa, Sho Yuasa, et al.
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 305
Targeting autophagy in obesity: from pathophysiology to management
Yingmei Zhang, James R. Sowers, Jun Ren
Nature Reviews Endocrinology (2018) Vol. 14, Iss. 6, pp. 356-376
Closed Access | Times Cited: 302
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Fabrice Bonnet, André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 6, pp. 457-464
Closed Access | Times Cited: 259
Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity
Maria J. Pereira, Jan W. Eriksson
Drugs (2019) Vol. 79, Iss. 3, pp. 219-230
Open Access | Times Cited: 257
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Milton Packer
Circulation (2022) Vol. 146, Iss. 18, pp. 1383-1405
Open Access | Times Cited: 252
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Jun Ren, Ne N. Wu, Shuyi Wang, et al.
Physiological Reviews (2021) Vol. 101, Iss. 4, pp. 1745-1807
Open Access | Times Cited: 251
Signaling pathways in obesity: mechanisms and therapeutic interventions
Xue Wen, Bohan Zhang, Beiyi Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 242
Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE(-/-) Mice by Activating Autophagy and Reducing ER Stress and Apoptosis
Narjes Nasiri‐Ansari, Chrysa Nikolopoulou, Katerina Papoutsi, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 818-818
Open Access | Times Cited: 223
SGLT2 inhibition reprograms systemic metabolism via FGF21-dependent and -independent mechanisms
Soravis Osataphan, Chiara Macchi, Garima Singhal, et al.
JCI Insight (2019) Vol. 4, Iss. 5
Open Access | Times Cited: 181
Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
Juan Antonio Requena-Ibáñez, Carlos G. Santos‐Gallego, Anderly Rodriguez-Cordero, et al.
JACC Heart Failure (2021) Vol. 9, Iss. 8, pp. 578-589
Closed Access | Times Cited: 181
Unraveling the Role of Inflammation in the Pathogenesis of Diabetic Kidney Disease
Keiichiro Matoba, Yusuke Takeda, Yosuke Nagai, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 14, pp. 3393-3393
Open Access | Times Cited: 169
Induction of Adipose Tissue Browning as a Strategy to Combat Obesity
Alina Kuryłowicz, Monika Puzianowska‐Kuźnicka
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 17, pp. 6241-6241
Open Access | Times Cited: 164
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Tuba M. Ansary, Daisuke Nakano, Akira Nishiyama
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 3, pp. 629-629
Open Access | Times Cited: 146
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Zsolt Szekeres, Kálmán Tóth, Eszter Szabados
Metabolites (2021) Vol. 11, Iss. 2, pp. 87-87
Open Access | Times Cited: 133
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Haleh Chehrehgosha, Masoudreza Sohrabi, Faramarz Ismail‐Beigi, et al.
Diabetes Therapy (2021) Vol. 12, Iss. 3, pp. 843-861
Open Access | Times Cited: 115
Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials
Lucia Scisciola, Vittoria Cataldo, Fatemeh Taktaz, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 79
Role of Epicardial Adipose Tissue in Cardiovascular Diseases: A Review
Michał Konwerski, Aleksandra Gąsecka, Grzegorz Opolski, et al.
Biology (2022) Vol. 11, Iss. 3, pp. 355-355
Open Access | Times Cited: 70
Adipose tissue macrophages as potential targets for obesity and metabolic diseases
Xirong Li, Yakun Ren, Ke-Wei Chang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 57
Metabolic-Dysfunction-Associated Steatotic Liver Disease—Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 20, pp. 15473-15473
Open Access | Times Cited: 47
Metaflammation in obesity and its therapeutic targeting
Michael W. Schleh, Heather L. Caslin, Jamie N. Garcia, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 723
Open Access | Times Cited: 44
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
Page 1 - Next Page

Scroll to top